Swiss Pharma Nigeria Limited (Swipha) has achieved a historic milestone by receiving World Health Organisation (WHO) prequalification for its Sulfadoxine Plus Pyrimethamine (SP) 500/25mg Tablet, aimed at preventing malaria during pregnancy. This significant achievement underscores Swipha’s commitment to enhancing maternal health and combating malaria, particularly in Nigeria and across Africa.
Malaria in pregnancy poses severe risks such as maternal anemia, low birth weight, preterm birth, and maternal death. Preventive measures, including the use of SP tablets during antenatal care, are crucial in mitigating these risks and improving health outcomes.
Frederic Lieutaud, Managing Director of Swipha, highlighted the significance of this prequalification, stating, “We are immensely proud to have received WHO Prequalification for our Sulfadoxine Plus Pyrimethamine Tablet for preventing malaria in pregnancy. This achievement reflects our commitment to delivering high-quality, life-saving medicines that meet international standards.”
Abbas Sambo, Business Development & Licensing Director at Swipha, emphasized the impact of this certification, noting that it enables the company to offer the SP Tablet to global organizations and governments, thus contributing to better maternal and child health outcomes. He also highlighted Swipha’s ongoing efforts to partner with entities like the Global Fund and USAID to address critical health challenges.
Sambo acknowledged the support of various partners, including Servier Generic Group, NAFDAC, Unitaid, Medicines for Malaria Venture (MMV), WHO, USAID, and others, whose expertise was crucial in achieving this milestone.
The National Agency for Food and Drug Administration and Control (NAFDAC) praised Swipha for its adherence to high pharmaceutical manufacturing standards. This WHO prequalification serves as an inspiration for local drug manufacturers to pursue similar certifications and improve the quality of pharmaceuticals in Nigeria and the region.
Swiss Pharma Nigeria Limited (Swipha) remains dedicated to providing high-quality, affordable medicines and making a positive impact on health outcomes in Nigeria and Africa.
